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eral blood stem cell product collected before treatment on this
study. Two patients achieved complete remission and remain pro-
gression-free more than 5 years after study entry. Four relapsed
and died of progressive disease; all recurred in extraosseous sites
with 2 also having disease in the bone marrow. Median time to
progression was 10 months.
We conclude that treatment with 166Ho DOTMP delivers tar-
geted radiotherapy to the skeleton with an acceptable toxicity
proﬁle. Two patients with bone-only metastases achieved sustained
complete responses. Further studies are warranted to evaluate this
strategy for treatment of bone metastases.
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TANDEM HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL
BLOOD STEM CELL RESCUE (PBSCR) AS CONSOLIDATION THERAPY
FOR HIGH-RISK (PRIMARY UNRESECTABLE PELVIC TUMORS OR MET-
ASTATIC DISEASE) EWING’S SARCOMA PATIENTS
Burke, M.J., Kletzel, M., Jacobsohn, D.A., Duerst, R.E. Children’s
Memorial Hospital, Feinberg School of Medicine, Northwestern Univer-
sity, Chicago, IL.
Methods: Between 1985 and 2004, 14 patients with high-risk
Ewing’s sarcoma received induction chemotherapy, surgery, and
radiation therapy, with 8 of the 14 patients receiving tandem
transplantations. The median age at diagnosis was 14 years (range,
1–17 years) for the 8 patients receiving PBSCR and 9 years (range,
4–14 years) for the 6 patients who did not receive PBSCR. Of the
6 patients who did not receive a stem cell rescue, 5 had primary
pelvic tumors without metastatic disease, and 1 had a nonpelvic
primary tumor with bone metastases. Of the 8 patients who re-
ceived HDC and PBSCR, 6 patients had primary pelvic tumors (3
of them with pulmonary metastases), and the remaining 2 had
primary bone disease outside of the pelvis with bone metastases. Of
the 8 patients who received a transplant, 2 received chemotherapy
only before PBSCR, and 6 received chemotherapy and surgery
before transplantation. Three ablative regimens were used for the
8 patients. Six patients received tandem rescues. Rescue 1 included
etoposide (VP-16), 800 mg/m2/day for 3 days; carboplatin (CP),
667 mg/m2/day for 3 days; and cyclophoshamide (CTX), 1800
mg/m2/day for 2 days. Rescue 2 involved thiotepa (TT), 300
mg/m2/day for 3 days; CTX (n  1), melphalan/CTX (n  4), and
melphalan/TBI (n  1); VP-16, 800 mg/m2/day for 4 days; CTX,
1800 mg/m2/day for 3 days; total body irradiation (TBI), 200 cGy
BID for 3 days (n 1); melphalan, 60 mg/m2/day for 3 days; CTX,
500 mg/m2/day for 4 days (n  1). The median stem cell dose was
1.78  108 mnc/kg (range, 1.0  108 to 2.3  108 mnc/kg).
Results: The mean time to achieve ANC  500 was 13 days
(range, 7–17 days), and the mean time to achieve a platelet count
20K for 7 consecutive days unsupported was 23 days (range, 7–57
days). There were no toxic deaths in the 8 patients who received
PBSCR. Five of the 8 patients who received PBSCR are in com-
plete remission, with a median follow-up of 7.8 years (range,
36–118 months). Of the 6 patients who did not receive PBSCR, 3
continue in complete remission with a median follow-up of 10.5
years (range, 120–132 months). Conclusions: Our results suggest
that high-dose therapy with PBSCR is an effective and feasible
treatment for patients with high-risk Ewing’s sarcoma. A larger
longitudinal study would be helpful to further evaluate this treat-
ment option.
STEM CELL BIOLOGY
251
CD133-POSITIVE HEMATOPOIETIC STEM CELLS “STEMNESS” GENES
CONTAIN MANY GENES MUTATED OR ABNORMALLY EXPRESSED IN
LEUKEMIA
Toren, A.1, Bielorai, B.1, Jacob-Hirsh, J.1, Fisher, T.1, Kreiser, D.1,
Zelikovsky, S.1, Givol, D.2, Itskovitz-Eldor, J.3, Rosenthal, E.1,
Amariglio, N.1, Rechavi, G.1 1Sheba Medical Center, Tel-Hashomer,
Israel; 2Weizmann Institute of Science, Rehovot, Israel; 3Rambam Med-
ical Center, Haifa, Israel.
Several groups have recently used microarray technology to
study the common characteristics of stem cells from different
tissues (“stemness”) and the typical features of stem cells from
various sources (“tissue speciﬁcity”). Most groups focused their
study on mice, used relatively small cDNA microarrays, and used
CD34 as the cell surface marker for hematopoietic stem cells
isolation. We studied HSC cells from cord blood (CB) and periph-
eral blood (PB)characterized by expression of the primitive CD133
antigen, and used the Affymetrix Human Hu133A oligonucleotide
arrays to study the gene expression proﬁle of these cells.
An unsupervised hierarchical clustering of 14,025 “valid” probe
sets showed a clear distinction between the CD133 cells repre-
senting the stem cell population and CD133 cells that represent
various stages of cell differentiation. Comparison of CD133 cells
isolated from CB and PB to CD133 cells identiﬁed 304 genes
that were up-regulated by at least 2-fold in CB and 218 genes in
PB. These genes were considered source-speciﬁc and possibly
relevant to the unique properties of CB- and PB-derived HSC. A
total of 244 genes were found to be up-regulated by at least 2-fold
in the CD133 cells of both CB and PB compared with the
CD133 cells. Comparison of these “stemness” genes to the lists
of “stemness” genes that were identiﬁed by 2 recent studies that
analyzed mainly murine HSC identiﬁed totals of 33 and 65 com-
mon genes. Twenty-four genes were common to another study
that analyzed human HSC.
Among these common “stemness” genes, we identiﬁed several
groups of genes that have an important role in hematopoiesis:
growth factor receptors, a group of transcription factors that in-
cludes several homeobox genes and TGF- target genes, genes
that have an important role in development, and genes involved in
cell growth. Among these 4 groups, we identiﬁed 16 “stemness”
genes (MPL, FLT3, HOXA9, MEIS 1, MLLT3, KIT, TIE,
GATA-2, HOXA5, HOXA10, HLF, MYCN, EVI1, MYB, FHL1,
and HMGA2) that are known to be mutated or abnormally regu-
lated in acute leukemias. It can be suggested that key hematopoi-
etic stemness machinery genes may lead to abnormal proliferation
and leukemia on mutation or change of expression.
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PLEIOTROPHIN IS A KEY SWITCH OF HUMAN MONOCYTES AND BONE
MARROW STEM CELLS INTO ENDOTHERLIAL-LIKE CELLS FOR ANGIO-
GENESIS IN TUMOR GROWTH
Chen, H.1, Zhu, D.1, Campbell, R.A.1, Pan-James, C.1, Wang, C.S.1,
Gordon, M.S.1,2, Bonavida, B.2, Berenson, J.R.1 1Institute for Myeloma
and Bone Cancer Research, West Hollywood, CA; 2UCLA School of
Medicine, Los Angeles, CA.
Multiple myeloma (MM) patients express pleiotrophin (PTN), a
secreted protein that binds CD138, and it is found at high levels in
the serum of MM patients. We have discovered a novel mechanism
leading to blood vessel formation by tumor cells. First, we puriﬁed
human monocytes (CD14) and cultured on collagen I, collagen
IV, ﬁbronectin, or laminin-coated dishes. The cells incubated on
collagen I (but not on the other 3 proteins) with mCSF  PTN
formed tube-like structures with positive staining for Flk-1. Com-
plex lines consisting of multiple rows of elongated Flk-1 cells in
contact with each other were found. In contrast, monocytes incu-
bated with only mCSF or on other substrates remained in sepa-
rated positions. We also cloned human monocytic THP-1 cells
with PTN sense or antisense whole sequencing DNA. We exam-
ined expression by RT-PCR of endothelial cell markers Flk-1,
Tie-2, and vWf and monocyte markers c-fms and CD68. THP-1
cells infected with PTN sense strand expressed high amounts of
Flk-1, Tie-2, and vWf similar to that found in human coronary
artery endothelial cells and lost expression of c-fms and CD68.
Next, we cultured THP1 monocytes with human myeloma
RPMI8226 cells in transwell cultures, serum derived from MM
patients with high serum levels of PTN, cell lines lacking PTN
expression, or normal controls lacking serum PTN. The THP-1
cells exposed to the MM cell line or MM serum showed expression
of endothelial markers. The expression of endothelial markers was
blocked by adding anti-PTN antibody. We also determined
whether PTN could also stimulate differentiation of bone marrow
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